Saitama-ken, Japan

Yukinori Masuda


Average Co-Inventor Count = 4.9

ph-index = 5

Forward Citations = 44(Granted Patents)


Location History:

  • Saitama, JP (1990)
  • Minamisaitama, JP (1993)
  • Saitama-ken, JP (1998 - 1999)
  • Chiyoda-ku, JP (2009)

Company Filing History:


Years Active: 1990-2009

Loading Chart...
8 patents (USPTO):Explore Patents

Title: The Innovations of Yukinori Masuda

Introduction

Yukinori Masuda is a prominent inventor based in Saitama-ken, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of calcium channel blockers. With a total of 8 patents to his name, Masuda continues to push the boundaries of medical science.

Latest Patents

One of his latest innovations is a T-type calcium channel blocker. This invention is an optically active 1,4-dihydropyridine compound, which can be a pharmaceutically acceptable salt or solvate. The formula includes various configurations of alkyl groups and phenyl groups, showcasing the complexity and potential of his work. Additionally, he has developed medicines aimed at treating cardiac insufficiency, further demonstrating his commitment to improving healthcare.

Career Highlights

Masuda's career is marked by his association with Nissan Chemical Industries Limited, where he has been able to apply his expertise in pharmaceutical chemistry. His work has not only advanced the field but has also contributed to the development of effective treatments for various medical conditions.

Collaborations

Throughout his career, Masuda has collaborated with notable colleagues such as Yoshimasa Kamikawaji and Keizo Tanikawa. These partnerships have allowed for the exchange of ideas and have fostered innovation in their respective fields.

Conclusion

Yukinori Masuda's contributions to the pharmaceutical industry are noteworthy, with his innovative patents paving the way for advancements in medical treatments. His dedication to research and collaboration continues to inspire future generations of inventors.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…